Montreal, Canada

Patrick Lypaczewski

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrick Lypaczewski. Retrieved from https://idiyas.com/inventor/patrick-lypaczewski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Patrick Lypaczewski and His Patent Work.

Introduction

Patrick Lypaczewski is an inventor associated with Montreal, Canada. His patent work includes research on vaccine approaches designed to improve safety.

Latest Patents

The supplied information lists one patent for Lypaczewski: “Live Attenuated Leishmania Parasite Vaccines with Enhanced Safety Characteristics.” The patent concerns live attenuated Leishmania parasites developed with enhanced safety characteristics. 1 patent is listed.

Career Highlights

The patent is assigned to the United States of America, as represented by the Secretary of the Department of Health and Human Services. This government organization is associated with the patent’s development and ownership.

Collaborations

Lypaczewski’s listed coworkers include Hira L. Nakhasi and Ranadhir Dey, who are also associated with the patent.

Conclusion

Patrick Lypaczewski’s listed invention focuses on a Leishmania vaccine approach with enhanced safety characteristics, developed in collaboration with colleagues and assigned to the U.S. Department of Health and Human Services.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…